• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Reproductive toxicology >Asthma, asthma medications and their effects on maternal/fetal outcomes during pregnancy.
【24h】

Asthma, asthma medications and their effects on maternal/fetal outcomes during pregnancy.

机译：哮喘，哮喘药物及其对孕妇孕产期/胎儿结局的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Maternal asthma may increase the risk of adverse fetal and maternal outcomes such as low birth weight, perinatal mortality, preterm birth, preeclampsia, hypertensive disorders, maternal mortality, uterine hemorrhage, and gestational diabetes. Controlling asthma during pregnancy with appropriate medications leads to improved intrauterine growth of the fetus and fewer adverse perinatal outcomes. Prospective population or birth cohort studies have shown that the medications used to treat asthma, such as bronchodilators (short-acting beta2-agonists) and controller medications (inhaled corticosteroids, cromones, theophylline, leukotriene inhibitors), have no or minimal effects on fetal growth, and perinatal complications are reduced when maternal asthma is adequately controlled. However, taking oral corticosteroids during pregnancy may confer increased risk of lower birth weight and congenital malformations. Therefore, managing pregnant asthmatics requires a careful benefit-risk analysis, and when indicated, the benefits of a medication that may have increased risks can dictate its use in severe uncontrolled asthma.
机译：产妇哮喘可能增加胎儿和产妇不良结局的风险，例如低体重，围产期死亡，早产，先兆子痫，高血压疾病，产妇死亡率，子宫出血和妊娠糖尿病。在怀孕期间使用适当的药物控制哮喘可以改善胎儿的宫内生长，并减少不良的围生期结局。预期的人群或出生队列研究表明，用于治疗哮喘的药物，例如支气管扩张药（短效β2受体激动剂）和控制药物（吸入皮质类固醇，激素，茶碱，白三烯抑制剂），对胎儿生长没有影响或影响很小。充分控制孕产妇哮喘后，围产期并发症会减少。但是，在怀孕期间服用口服皮质类固醇可能会增加降低出生体重和先天性畸形的风险。因此，管理怀孕的哮喘患者需要仔细的获益风险分析，并且在有可能的情况下，风险可能增加的药物的获益可能会决定其在严重的不受控制的哮喘中的使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号